Roche

News

Pandemic and currency headwinds hurt Roche in first half

Roche has announced half-year results showing the COVID-19 pandemic affected sales of its key products, with currency headwinds also weighing on revenues.

News

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.

News

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery.

News

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

Pandemic and currency headwinds hurt Roche in first half

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

Amgen's cancer biosimilars stay on US market as court battle...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

NICE green lights Roche’s Rozlytrek for NTRK tumours

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks